ICER finds Vertex's non-opioid pain treatment could bring cost savings at a lower price

The cost-effectiveness watchdog ICER found that Vertex’s future non-opioid treatment for acute pain could be cost-saving, but only at a low price, according to a draft report released on Monday by the organization. ICER used ...